# FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

> **NCT05432193** · PHASE1 · TERMINATED · sponsor: **POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- Esophageal Cancer
- Melanoma (Skin)
- Soft Tissue Sarcoma
- Head and Neck Squamous Cell Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** [Ga-68]-PNT6555
- **DRUG:** [Lu-177]-PNT6555

## Key facts

- **NCT ID:** NCT05432193
- **Lead sponsor:** POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-13
- **Primary completion:** 2023-11-10
- **Final completion:** 2024-10-02
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432193, "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05432193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*